AstraZeneca is in talks with Bristol Myers Squibb on a $400 billion megadeal, according to the Financial Times. This was reported by Qazaqyia.kz citing Reuters.
According to the information, the potential deal between the two pharmaceutical companies is valued at $400 billion. This could be one of the largest deals in the industry.
In a Reuters report citing FT sources, it is stated that the talks are at an early stage and there is no guarantee the deal will be completed. The companies have not officially commented on the matter.
If the deal goes through, it would be a historic event in the pharmaceutical industry. AstraZeneca and Bristol Myers Squibb are among the world's leading pharmaceutical companies, and their merger could significantly shift market dynamics.
Further details are expected.